Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at ABIOMED INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ABIOMED INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ABIOMED INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Michael R. Minogue
Chairman of the Board, President, Chief Executive Officer
Total Cash $3,026,467 Equity $9,630,285 Other $9,240 Total Compensation $12,665,992
Andrew Greenfield
Executive Vice President and Chief Commercial Officer
Total Cash $795,706 Equity $2,031,097 Other $9,240 Total Compensation $2,836,043
David M. Weber
Former Senior Vice President and Chief Operating Officer
Total Cash $1,006,293 Equity $1,271,705 Other $9,240 Total Compensation $2,287,238
Todd A. Trapp
Executive Vice President, Chief Financial Officer
Total Cash $905,690 Equity $2,126,060 Other $9,240 Total Compensation $3,040,990
Marc A. Began
Executive Vice President, General Counsel
Total Cash $809,400 Equity $1,748,222 Other $9,240 Total Compensation $2,566,862
For its 2022 fiscal year, ABIOMED INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Michael R. Minogue CEO Pay $12,665,992 Median Employee Pay $131,893 CEO Pay Ratio 96:1
For its 2022 fiscal year, ABIOMED INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Christopher D. Van Gorder Total Cash $264,300
Dorothy E. Puhy Total Cash $299,300
Eric A. Rose Total Cash $259,300
Jeannine M. Rivet Total Cash $266,800
Martin P. Sutter Total Cash $266,800
Myron L. Rolle Total Cash $259,300
Paul G. Thomas Total Cash $269,300
Paula A. Johnson Total Cash $499,891
W. Gerald Austen Total Cash $254,300

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.